Arrowhead Pharmaceuticals Q4 Earnings Call Highlights
Arrowhead Pharmaceuticals reported Q4 earnings, highlighting increased prescriptions for its drugs and potential future sales. The company expects $3B-$4B in annual U.S. sales for REDEMPLO if approved for SHTG. Operating expenses rose to $1.16B, but cash reserves increased to $1.2B. Arrowhead plans to track key metrics for an SHTG launch and has upcoming pipeline milestones in 2027.
How this was made
The 30-second read
Why it matters
The earnings miss and higher loss are likely to drive the stock lower in after‑hours trading.
Market read
First disclosure of FY2026 Q4 results; material impact on ARWR valuation.
What to watch
Strong cash position and $400M loan at lower rates may provide runway for future growth.
Background
Arrowhead Pharmaceuticals provided its FY2026 Q4 earnings call highlights, including revenue, expenses, cash, and pipeline updates.
Ticker impact
Q4 earnings call disclosed FY2026 revenue of $450.8M, down from $829.4M, and operating expenses of $1.16B, resulting in a loss.
downward pressure as investors price in weaker revenue and higher loss
Revenue fell sharply and operating loss widened, which typically triggers a sell‑off in biotech stocks.
Market effects
Biotech sector may see broader pressure as earnings miss highlights execution risk.
U.S. biotech stocks could underperform in the near term.
Limited to investors tracking U.S. biotech earnings; no immediate global macro effect.
Counterpoint
If the new bridge program accelerates adoption, the stock could rebound despite short‑term miss.
Key entities
- CompanyArrowhead Pharmaceuticals
Biotech firm developing RNAi therapeutics (NASDAQ: ARWR).
